CA2997399C - 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer - Google Patents

8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer Download PDF

Info

Publication number: CA2997399C
Authority: CA; Canada
Prior art keywords: fluoro; methyl; imidazo; isopropy1; quinolin
Prior art date: 2015-09-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2997399A

Other languages

English (en)

French (fr)

Other versions

CA2997399A1 (en

Inventor

Kurt Gordon Pike

Bernard Christophe Barlaam

Thomas Anthony Hunt

Andrew John Eatherton

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

AstraZeneca AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-17

Filing date

2016-09-15

Publication date

2024-02-20

2016-09-15 Application filed by AstraZeneca AB filed Critical AstraZeneca AB

2017-03-23 Publication of CA2997399A1 publication Critical patent/CA2997399A1/en

2024-02-20 Application granted granted Critical

2024-02-20 Publication of CA2997399C publication Critical patent/CA2997399C/en

Status Active legal-status Critical Current

2036-09-15 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA2997399A 2015-09-17 2016-09-15 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer Active CA2997399C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB1516504.6		2015-09-17
GBGB1516504.6A GB201516504D0 (en)	2015-09-17	2015-09-17	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
PCT/EP2016/071782 WO2017046216A1 (en)	2015-09-17	2016-09-15	8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Publications (2)

Publication Number	Publication Date
CA2997399A1 CA2997399A1 (en)	2017-03-23
CA2997399C true CA2997399C (en)	2024-02-20

Family

ID=54544418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2997399A Active CA2997399C (en)	2015-09-17	2016-09-15	8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer

Country Status (37)

Country	Link
US (5)	US9856255B2 (es)
EP (2)	EP3350180B1 (es)
JP (1)	JP6605130B2 (es)
KR (2)	KR102469153B1 (es)
CN (1)	CN108137576B (es)
AR (1)	AR106053A1 (es)
AU (1)	AU2016323399B2 (es)
BR (1)	BR112018004325B1 (es)
CA (1)	CA2997399C (es)
CL (1)	CL2018000677A1 (es)
CO (1)	CO2018002829A2 (es)
CR (1)	CR20180172A (es)
CY (1)	CY1124680T1 (es)
DK (2)	DK3683220T3 (es)
DO (1)	DOP2018000065A (es)
EA (1)	EA033284B1 (es)
ES (2)	ES2920876T3 (es)
GB (1)	GB201516504D0 (es)
HR (1)	HRP20210149T1 (es)
HU (2)	HUE058884T2 (es)
IL (1)	IL257847B (es)
LT (1)	LT3350180T (es)
MX (1)	MX384930B (es)
MY (2)	MY198813A (es)
NI (1)	NI201800033A (es)
PE (1)	PE20181078A1 (es)
PH (1)	PH12018500532A1 (es)
PL (2)	PL3683220T3 (es)
PT (2)	PT3350180T (es)
RS (1)	RS61435B1 (es)
SI (1)	SI3350180T1 (es)
SM (1)	SMT202100071T1 (es)
SV (1)	SV2018005655A (es)
TN (1)	TN2018000078A1 (es)
TW (2)	TWI762109B (es)
WO (1)	WO2017046216A1 (es)
ZA (1)	ZA202209171B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201516504D0 (en) *	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) *	2016-05-11	2016-06-22	Astrazeneca Ab	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JOP20190209A1 (ar) *	2017-03-16	2019-09-12	Astrazeneca Ab	مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
WO2019057757A1 (en)	2017-09-20	2019-03-28	Astrazeneca Ab	1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
ES3001444T3 (en)	2018-09-14	2025-03-05	Suzhou Zanrong Pharma Ltd	1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
WO2021139814A1 (zh) *	2020-01-09	2021-07-15	南京明德新药研发有限公司	喹啉并咪唑类化合物及其应用
JP7407298B2 (ja) *	2020-03-04	2023-12-28	ファロス・アイバイオ・カンパニー・リミテッド	２，３，５－置換されたチオフェン化合物の卵巣癌の予防、改善または治療用途
EP4171651A1 (en) *	2020-06-24	2023-05-03	AstraZeneca UK Limited	Combination of antibody-drug conjugate and atm inhibitor
EP4219499A4 (en) *	2020-09-28	2025-04-02	CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.	A class of fused ring compounds, and preparation and use thereof
EP3992191A1 (en)	2020-11-03	2022-05-04	Deutsches Krebsforschungszentrum	Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022125614A1 (en) *	2020-12-09	2022-06-16	Stingray Therapeutics, Inc.	Phosphonates as inhibitors of enpp1 and cdnp
AU2021433713A1 (en) *	2021-03-17	2023-09-28	Suzhou Zanrong Pharma Limited	Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115304598B (zh) *	2021-08-25	2024-05-31	石药集团中奇制药技术（石家庄）有限公司	一种杂环类化合物及其制备方法和用途
GB202114704D0 (en)	2021-10-14	2021-12-01	Univ Birmingham	ATM inhibition
WO2023143282A1 (zh) *	2022-01-26	2023-08-03	正大天晴药业集团股份有限公司	含有肼基的化合物
US20250179067A1 (en) *	2022-04-11	2025-06-05	Wei Zhong	Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application
WO2024214685A1 (ja)	2023-04-10	2024-10-17	第一三共株式会社	抗ｂ７－ｈ３抗体－薬物コンジュゲートとａｔｒ阻害剤又はａｔｍ阻害剤との組み合わせ
TW202529760A (zh)	2023-09-13	2025-08-01	瑞典商阿斯特捷利康公司	治療方法
TW202535383A (zh)	2024-03-13	2025-09-16	瑞典商阿斯特捷利康公司	治療方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992006683A1 (en)	1990-10-22	1992-04-30	Research Corporation Technologies, Inc.	Aryl and heteroaryl compounds having anti-retrovirus activity
TW301607B (es)	1993-03-09	1997-04-01	Takeda Pharm Industry Co Ltd
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
KR19990082463A (ko)	1996-02-13	1999-11-25	돈 리사 로얄	혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6632823B1 (en)	1997-12-22	2003-10-14	Merck & Co., Inc.	Substituted pyridine compounds useful as modulators of acetylcholine receptors
EP1107759A1 (en)	1998-08-03	2001-06-20	Basf Corporation	Pyridinones for the treatment of sexual dysfunction
CA2362401A1 (en)	1999-02-04	2000-08-10	Paul Fleming	G-protein coupled heptahelical receptor binding compounds and methods of use thereof
US20020151712A1 (en)	1999-09-14	2002-10-17	Nan-Horng Lin	3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
US20020132836A1 (en)	2000-10-11	2002-09-19	Chemocentryx Inc.	Compounds and methods for modulating CCR4 function
AU2002213467A1 (en)	2000-10-11	2002-04-22	Chemocentryx, Inc.	Modulation of ccr4 function
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
WO2002076177A2 (en)	2001-03-23	2002-10-03	Bethesda Pharmaceuticals, Inc.	Design and synthesis of optimized ligands for ppar
JP2002293745A (ja)	2001-03-29	2002-10-09	St Marianna Univ School Of Medicine	慢性関節リウマチ治療剤
CA2442654A1 (en)	2001-04-10	2002-10-10	Transtech Pharma, Inc.	Probes, systems, and methods for drug discovery
WO2002087618A1 (en)	2001-04-27	2002-11-07	Takeda Chemical Industries, Ltd.	Preventive/therapeutic method for cancer
US7144903B2 (en)	2001-05-23	2006-12-05	Amgen Inc.	CCR4 antagonists
EP1270535A3 (de)	2001-06-20	2004-02-18	Clariant GmbH	Verfahren zur Herstellung von substituierten aromatischen Verbindungen
JP4082888B2 (ja)	2001-10-17	2008-04-30	広栄化学工業株式会社	ビアリール化合物の製造法
CA2473740A1 (en)	2002-01-18	2003-07-31	David Solow-Cordero	Methods of treating conditions associated with an edg receptor
JP4167848B2 (ja)	2002-04-10	2008-10-22	広栄化学工業株式会社	ビアリール化合物の製造法
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
AU2003252478A1 (en)	2002-07-10	2004-02-02	Ono Pharmaceutical Co., Ltd.	Ccr4 antagonist and medicinal use thereof
CA2496097A1 (en)	2002-08-23	2004-03-04	University Of Connecticut	Keto cannabinoids with therapeutic indications
JP2005536554A (ja)	2002-08-23	2005-12-02	ユニバーシティオブコネチカット	新規なビフェニル及びビフェニル様カンナビノイド
US7432375B2 (en) *	2003-03-06	2008-10-07	Eisai R & D Management Co., Ltd.	JNK inhibitors
WO2004080943A1 (ja)	2003-03-11	2004-09-23	Ono Pharmaceutical Co., Ltd.	シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
WO2004113258A1 (ja)	2003-06-20	2004-12-29	Shionogi & Co., Ltd.	炭素−炭素結合生成反応
WO2005023771A1 (ja)	2003-09-05	2005-03-17	Ono Pharmaceutical Co., Ltd.	ケモカインレセプターアンタゴニストおよびその医薬用途
JP2005170939A (ja)	2003-11-20	2005-06-30	Takeda Chem Ind Ltd	糖尿病の予防・治療剤
WO2005054237A1 (en)	2003-11-21	2005-06-16	Novartis Ag	1h-imidazoquinoline derivatives as protein kinase inhibitors
WO2006038594A1 (ja)	2004-10-04	2006-04-13	Ono Pharmaceutical Co., Ltd.	Ｎ型カルシウムチャネル阻害薬
AU2005314938B2 (en)	2004-12-13	2011-06-09	Ono Pharmaceutical Co., Ltd.	Aminocarboxylic acid derivative and medicinal use thereof
GB0510390D0 (en) *	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US20070032522A1 (en)	2005-07-01	2007-02-08	Kumar Dange V	Antiviral agents
WO2007025187A2 (en)	2005-08-26	2007-03-01	Emory University	Compounds and methods for modulating the silencing of a polynucleotide of interest
JO3598B1 (ar)	2006-10-10	2020-07-05	Infinity Discovery Inc	الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP2009023986A (ja)	2006-11-08	2009-02-05	Pharma Ip	抗癌剤としてのビアリール誘導体
CL2008000191A1 (es)	2007-01-25	2008-08-22	Astrazeneca Ab	Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
EP2129379B1 (en)	2007-02-20	2019-04-10	Novartis AG	Imidazoquinolines as dual lipid kinase and mtor inhibitors
MX2009009540A (es)	2007-03-07	2009-09-16	Alantos Pharm Holding	Inhibidores de metaloproteasa que contienen una porcion heterociclica.
US8039505B2 (en)	2007-04-11	2011-10-18	University Of Utah Research Foundation	Compounds for modulating T-cells
PE20090717A1 (es)	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US9321730B2 (en)	2007-08-21	2016-04-26	The Hong Kong Polytechnic University	Method of making and administering quinoline derivatives as anti-cancer agents
US9493419B2 (en)	2007-08-21	2016-11-15	The Hong Kong Polytechnic University	Quinoline derivatives as anti-cancer agents
EP2276488A1 (en)	2008-03-26	2011-01-26	Novartis AG	5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
CN102137847B (zh)	2008-07-01	2015-06-10	健泰科生物技术公司	作为mek激酶抑制剂的二环杂环
TW201028381A (en)	2008-07-14	2010-08-01	Shionogi & Co	Pyridine derivative having ttk inhibition activity
US8791131B2 (en)	2008-09-30	2014-07-29	Pfizer Inc.	Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
MX2011006108A (es)	2008-12-08	2011-11-18	Vm Pharma Llc	Composiciones de inhibidores de los receptores tirosina quinasa.
US20120093917A1 (en)	2009-04-02	2012-04-19	Robert Hromas	Metnase and intnase inhibitors and their use in treating cancer
TW201041888A (en)	2009-05-06	2010-12-01	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
US20100311714A1 (en) *	2009-06-04	2010-12-09	Pascal Furet	1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
KR101445458B1 (ko) *	2009-06-04	2014-10-07	노파르티스 아게	１Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체
NZ599090A (en)	2009-09-28	2014-02-28	Hoffmann La Roche	Benzoxepin pi3k inhibitor compounds and methods of use
GB0919423D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
CN102199152A (zh)	2010-03-25	2011-09-28	高大新	杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) *	2010-08-18	2014-09-17	山东轩竹医药科技有限公司	咪唑并喹啉类PI3K和mTOR双重抑制剂
US20120046272A1 (en)	2010-08-23	2012-02-23	Grunenthal Gmbh	Novel Therapeutic Compounds
DE102010035744A1 (de) *	2010-08-28	2012-03-01	Merck Patent Gmbh	Imidazolonylchinoline
CN102399218A (zh) *	2010-09-16	2012-04-04	和记黄埔医药（上海）有限公司	一类并合三杂环及其作为pi3k抑制剂的用途
AR083267A1 (es)	2010-10-04	2013-02-13	Novartis Ag	Combinaciones farmaceuticas
SG190210A1 (en)	2010-12-03	2013-06-28	Novartis Ag	Pharmaceutical compositions
CN103402520A (zh)	2010-12-06	2013-11-20	皮拉马尔企业有限公司	具有取代基的咪唑并喹啉衍生物
TWI450891B (zh)	2010-12-29	2014-09-01	Dev Center Biotechnology	新穎微管蛋白抑制劑
JO3003B1 (ar) *	2011-01-14	2016-09-05	Lilly Co Eli	مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US20140287931A1 (en)	2011-04-04	2014-09-25	Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis	Methods and compositions for predicting resistance to anticancer treatment
BR112013030095A2 (pt)	2011-05-23	2019-09-24	Elan Pharm Inc	inibidores de atividade de lrrk2 cinase
CA2837312A1 (en)	2011-05-26	2012-11-29	Sunovion Pharmaceuticals Inc.	Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
WO2013022740A2 (en)	2011-08-05	2013-02-14	Corning Incorporated	Gpr35 ligands and the uses thereof
JP6042060B2 (ja)	2011-09-26	2016-12-14	サノフイ	ピラゾロキノリノン誘導体、その調製および治療上の使用
US9580409B2 (en)	2011-11-07	2017-02-28	Sunovion Pharmaceuticals, Inc.	Modulators of opioid receptors and methods of use thereof
WO2013074965A1 (en)	2011-11-16	2013-05-23	Microbiotix, Inc.	Aminoalkyl phenol ether inhibitors of influenza a virus
WO2013157018A1 (en)	2012-04-18	2013-10-24	Indian Institute Of Technology Madras	A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics
KR20150017367A (ko)	2012-06-06	2015-02-16	노파르티스 아게	종양 질환을 치료하기 위한 17-알파-히드록실라제 (c17,20-리아제) 억제제와 특이적 pi-3k 억제제의 조합물
CA2875964C (en)	2012-06-07	2018-01-02	Georgia State University Research Foundation, Inc.	Seca inhibitors and methods of making and using thereof
WO2013192367A1 (en)	2012-06-22	2013-12-27	Novartis Ag	Neuroendocrine tumor treatment
IN2015DN00528A (es)	2012-08-16	2015-06-26	Novartis Ag
WO2014031872A2 (en)	2012-08-23	2014-02-27	The Broad Institute, Inc.	Small molecule inhibitors for treating parasitic infections
CA2905830C (en)	2013-03-12	2022-01-18	Curegenix Inc.	Quinazoline and naphthyridine derivatives useful in the treatment of cancer
GB201309180D0 (en)	2013-05-21	2013-07-03	Ucl Business Plc	Compounds and Their Uses
WO2015073804A2 (en)	2013-11-15	2015-05-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Method of blocking transmission of malarial parasite
JP2016540773A (ja) *	2013-12-06	2016-12-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用な化合物
NO2714752T3 (es) *	2014-05-08	2018-04-21
GB201409044D0 (en)	2014-05-21	2014-07-02	Ucl Business Plc	New compounds
RS62082B1 (sr)	2015-04-02	2021-08-31	Merck Patent Gmbh	Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
CN104876912B (zh)	2015-04-08	2017-07-21	苏州云轩医药科技有限公司	Wnt信号通路抑制剂及其应用
EP3319938B1 (en)	2015-07-10	2022-04-06	University of Maryland, Baltimore	Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
GB201516504D0 (en) *	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
RS64261B1 (sr)	2016-03-16	2023-07-31	Kura Oncology Inc	Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe

2015
- 2015-09-17 GB GBGB1516504.6A patent/GB201516504D0/en not_active Ceased
2016
- 2016-09-14 TW TW109145998A patent/TWI762109B/zh active
- 2016-09-14 TW TW105129931A patent/TWI714631B/zh active
- 2016-09-15 HU HUE20156172A patent/HUE058884T2/hu unknown
- 2016-09-15 JP JP2018513812A patent/JP6605130B2/ja active Active
- 2016-09-15 EP EP16770461.8A patent/EP3350180B1/en active Active
- 2016-09-15 BR BR112018004325-7A patent/BR112018004325B1/pt active IP Right Grant
- 2016-09-15 CA CA2997399A patent/CA2997399C/en active Active
- 2016-09-15 EP EP20156172.7A patent/EP3683220B1/en active Active
- 2016-09-15 PT PT167704618T patent/PT3350180T/pt unknown
- 2016-09-15 MY MYPI2023000366A patent/MY198813A/en unknown
- 2016-09-15 PT PT201561727T patent/PT3683220T/pt unknown
- 2016-09-15 TN TNP/2018/000078A patent/TN2018000078A1/en unknown
- 2016-09-15 RS RS20210170A patent/RS61435B1/sr unknown
- 2016-09-15 SI SI201631074T patent/SI3350180T1/sl unknown
- 2016-09-15 DK DK20156172.7T patent/DK3683220T3/da active
- 2016-09-15 MY MYPI2018701049A patent/MY195669A/en unknown
- 2016-09-15 CR CR20180172A patent/CR20180172A/es unknown
- 2016-09-15 HR HRP20210149TT patent/HRP20210149T1/hr unknown
- 2016-09-15 WO PCT/EP2016/071782 patent/WO2017046216A1/en not_active Ceased
- 2016-09-15 ES ES20156172T patent/ES2920876T3/es active Active
- 2016-09-15 PE PE2018000343A patent/PE20181078A1/es unknown
- 2016-09-15 PL PL20156172.7T patent/PL3683220T3/pl unknown
- 2016-09-15 MX MX2018003186A patent/MX384930B/es unknown
- 2016-09-15 ES ES16770461T patent/ES2853924T3/es active Active
- 2016-09-15 AU AU2016323399A patent/AU2016323399B2/en active Active
- 2016-09-15 HU HUE16770461A patent/HUE053066T2/hu unknown
- 2016-09-15 EA EA201890650A patent/EA033284B1/ru not_active IP Right Cessation
- 2016-09-15 KR KR1020197028342A patent/KR102469153B1/ko active Active
- 2016-09-15 LT LTEP16770461.8T patent/LT3350180T/lt unknown
- 2016-09-15 DK DK16770461.8T patent/DK3350180T3/da active
- 2016-09-15 KR KR1020187010323A patent/KR102028848B1/ko active Active
- 2016-09-15 SM SM20210071T patent/SMT202100071T1/it unknown
- 2016-09-15 PL PL16770461T patent/PL3350180T3/pl unknown
- 2016-09-15 CN CN201680052951.0A patent/CN108137576B/zh active Active
- 2016-09-16 US US15/267,398 patent/US9856255B2/en active Active
- 2016-09-16 AR ARP160102832A patent/AR106053A1/es active IP Right Grant
2017
- 2017-11-27 US US15/822,617 patent/US10457679B2/en active Active
2018
- 2018-02-26 NI NI201800033A patent/NI201800033A/es unknown
- 2018-03-04 IL IL257847A patent/IL257847B/en active IP Right Grant
- 2018-03-06 DO DO2018000065A patent/DOP2018000065A/es unknown
- 2018-03-12 PH PH12018500532A patent/PH12018500532A1/en unknown
- 2018-03-14 CL CL2018000677A patent/CL2018000677A1/es unknown
- 2018-03-16 CO CONC2018/0002829A patent/CO2018002829A2/es unknown
- 2018-03-16 SV SV2018005655A patent/SV2018005655A/es unknown
2019
- 2019-09-27 US US16/584,996 patent/US10882858B2/en active Active
2020
- 2020-12-01 US US17/108,117 patent/US11613539B2/en active Active
2021
- 2021-02-11 CY CY20211100117T patent/CY1124680T1/el unknown
2022
- 2022-08-16 ZA ZA2022/09171A patent/ZA202209171B/en unknown
2023
- 2023-02-21 US US18/171,735 patent/US20230286981A1/en active Pending

Also Published As

Publication number	Publication date
ES2920876T3 (es)	2022-08-11
US20170081325A1 (en)	2017-03-23
PE20181078A1 (es)	2018-07-05
SV2018005655A (es)	2018-04-27
US9856255B2 (en)	2018-01-02
TN2018000078A1 (en)	2019-07-08
BR112018004325A2 (es)	2018-10-02
PL3350180T3 (pl)	2021-05-17
MY198813A (en)	2023-09-29
MY195669A (en)	2023-02-03
CA2997399A1 (en)	2017-03-23
TW202124381A (zh)	2021-07-01
WO2017046216A1 (en)	2017-03-23
KR102469153B1 (ko)	2022-11-22
KR20180052724A (ko)	2018-05-18
PT3350180T (pt)	2021-02-08
JP2018531226A (ja)	2018-10-25
US11613539B2 (en)	2023-03-28
TWI714631B (zh)	2021-01-01
TW201722946A (zh)	2017-07-01
CN108137576A (zh)	2018-06-08
CL2018000677A1 (es)	2018-08-17
EA201890650A1 (ru)	2018-10-31
US10457679B2 (en)	2019-10-29
BR112018004325B1 (pt)	2023-10-17
PL3683220T3 (pl)	2022-08-01
AR106053A1 (es)	2017-12-06
US20230286981A1 (en)	2023-09-14
EP3350180B1 (en)	2020-11-11
EP3683220B1 (en)	2022-04-13
SMT202100071T1 (it)	2021-03-15
HK1257413A1 (en)	2019-10-18
GB201516504D0 (en)	2015-11-04
AU2016323399B2 (en)	2019-04-18
HRP20210149T1 (hr)	2021-03-19
DK3350180T3 (da)	2021-02-15
PH12018500532A1 (en)	2018-08-29
ES2853924T3 (es)	2021-09-20
EP3683220A1 (en)	2020-07-22
NI201800033A (es)	2018-10-18
HUE058884T2 (hu)	2022-09-28
KR20190112852A (ko)	2019-10-07
IL257847B (en)	2020-08-31
CY1124680T1 (el)	2022-07-22
DK3683220T3 (da)	2022-07-04
CR20180172A (es)	2018-05-25
HK1255408A1 (zh)	2019-08-16
EA033284B1 (ru)	2019-09-30
KR102028848B1 (ko)	2019-10-04
AU2016323399A1 (en)	2018-05-10
JP6605130B2 (ja)	2019-11-13
CN108137576B (zh)	2020-09-22
US20210147416A1 (en)	2021-05-20
EP3350180A1 (en)	2018-07-25
US20180141943A1 (en)	2018-05-24
SI3350180T1 (sl)	2021-03-31
PT3683220T (pt)	2022-06-24
ZA202209171B (en)	2023-11-29
CO2018002829A2 (es)	2018-05-31
IL257847A (en)	2018-04-30
NZ741661A (en)	2024-04-26
MX384930B (es)	2025-03-14
HUE053066T2 (hu)	2021-06-28
LT3350180T (lt)	2021-02-25
US20200102302A1 (en)	2020-04-02
MX2018003186A (es)	2018-05-17
TWI762109B (zh)	2022-04-21
RS61435B1 (sr)	2021-03-31
US10882858B2 (en)	2021-01-05
DOP2018000065A (es)	2018-03-30

Publication	Publication Date	Title
CA2997399C (en)	2024-02-20	8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
CA2946459C (en)	2022-07-12	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP2018531226A6 (ja)	2018-12-13	癌の治療のための血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターとしての８−［６−［３−（アミノ）プロポキシ］−３−ピリジル］−１−イソプロピル−イミダゾ［４，５−ｃ］キノリン−２−オン誘導体
WO2017194632A1 (en)	2017-11-16	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2017153578A1 (en)	2017-09-14	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3596076A1 (en)	2020-01-22	Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CA3017035A1 (en)	2017-09-28	Cinnolin-4-amine compounds and their use in treating cancer
HK1257413B (en)	2021-05-21	8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
HK40034061B (en)	2022-07-15	8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of huntington’s disease
HK40034061A (en)	2021-04-23	8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of huntington’s disease
HK1255408B (en)	2021-06-11	8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-one derivatives

Legal Events

Date	Code	Title	Description
2021-09-24	EEER	Examination request	Effective date: 20210910
2022-07-27	EEER	Examination request	Effective date: 20210910
2022-10-22	EEER	Examination request	Effective date: 20210910
2023-01-18	EEER	Examination request	Effective date: 20210910
2023-07-27	EEER	Examination request	Effective date: 20210910
2023-08-17	EEER	Examination request	Effective date: 20210910
2023-09-08	EEER	Examination request	Effective date: 20210910
2023-12-07	EEER	Examination request	Effective date: 20210910
2024-01-10	EEER	Examination request	Effective date: 20210910